Recent molecular studies of fetal hemoglobin (HbF) regulation have shown promise for the development of clinical HbF inducers to be used in patients with β-thalassemia and sickle cell disease. However, while numerous promising inducers of HbF, have been studied at past in βthalassemia patient with limited success resulted no universally effective agents. Increased production of fetal hemoglobin (HbF) can ameliorate the severity of both β-thalassemia and sickle cell disease (SCD), the major disorders of β-hemoglobin. The defective production of the β-globin molecule in patients with β-thalassemia can be compensated for by an increase in the production of the β-like globin molecule, γ-globin, which pairs together with α-globin chains to form HbF. Here we examined the clinical studies of one HbF inducer Trans-Resveratrol and found Complete Response (52.2%), Partial Response (18.2%) and Non response (15.9%) in patients who, after more than one year of treatment, remained at the different level of transfusion dependency with extended transfusion intervals. The present study is to provide a resource that will be valuable for the design of future studies of HbF inducers in β-thalassemia. According to our knowledge and literature review, probably this could be the first report for resveratrol clinical trial in eastern Indian population.

No abstract